Nan Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nan Hu has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Tao Tang
Department of Vascular Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, #321 Zhongshan Road, Nanjing, Jiangsu, 210008, PR China
6 shared publicationsChuang Wang
Department of Vascular Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China
5 shared publications- Xiao-Qiang Li
Department of Vascular Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, #321 Zhongshan Road, Nanjing, Jiangsu, 210008, PR China
5 shared publications Shenglin Ye
Department of Vascular Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, #321 Zhongshan Road, Nanjing, Jiangsu, 210008, PR China
4 shared publications- Xiaolong Du
Kentucky Spinal Cord Injury Research Center, University of Louisville, Louisville, KY, United States;Spinal Cord and Brain Injury Research Group, Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, USA;Drum Tower Hospital Affiliated to Nanjing University School of Medicine, USA
4 shared publications Sheng-Lin Ye
Department of Vascular Surgery, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, China
3 shared publications
Latest Publications
- Open Access
- 1 November 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 65, 809-828
Artificial platelets suppressing deep vein thrombosis via competitive adhesion
Deep vein thrombosis (DVT) remains a therapeutic challenge, primarily driven by pathological platelet adhesion at sites of vascular injury mediated by endothelial adhesion molecule overexpression. However, the molecular mechanisms underlying endothelial-dependent pathological platelet adhesion remain elusive. Here, integrating single-cell RNA sequencing (scRNA-seq) and functional validation, we identified aberrant activation of the stimulator of interferon genes (STING) as a critical driver of endothelial dysfunction and pathological platelet adhesion. Using STING knockout mice, we confirmed its central role in promoting a prothrombotic microenvironment via the NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome. Targeting this pathway, we identified forsythoside A (FA) as a potent STING inhibitor and constructed artificial platelets (Pm@Fng) via photopolymerization-membrane extrusion technology. Pm@Fng, consisting of FA-loaded nanogels cloaked with activated platelet membrane vesicles (APMVs), exhibited enhanced glycoprotein Ib alpha (GPIbα) -mediated binding affinity to von Willebrand factor (vWF), competitively blocking pathological platelet adhesion. Under thrombotic microenvironment (acidic pH and high reactive oxygen species), FA was released to modulate the STING - NLRP3 pathway, suppressing adhesion molecule expression. In a mouse DVT model, Pm@Fng rapidly targeted the endothelium, noticeably reducing thrombosis by 30% (p < 0.001) and preserving endothelial integrity. By exploiting competitive adhesion principles, this study presents a novel therapeutic strategy for DVT and other endothelial injury-related diseases.
- 1 November 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 65, 809-828
Open AccessArtificial platelets suppressing deep vein thrombosis via competitive adhesion
Deep vein thrombosis (DVT) remains a therapeutic challenge, primarily driven by pathological platelet adhesion at sites of vascular injury mediated by endothelial adhesion molecule overexpression. However, the molecular mechanisms underlying endothelial-dependent pathological platelet adhesion remain elusive. Here, integrating single-cell RNA sequencing (scRNA-seq) and functional validation, we identified aberrant activation of the stimulator of interferon genes (STING) as a critical driver of endothelial dysfunction and pathological platelet adhesion. Using STING knockout mice, we confirmed its central role in promoting a prothrombotic microenvironment via the NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome. Targeting this pathway, we identified forsythoside A (FA) as a potent STING inhibitor and constructed artificial platelets (Pm@Fng) via photopolymerization-membrane extrusion technology. Pm@Fng, consisting of FA-loaded nanogels cloaked with activated platelet membrane vesicles (APMVs), exhibited enhanced glycoprotein Ib alpha (GPIbα) -mediated binding affinity to von Willebrand factor (vWF), competitively blocking pathological platelet adhesion. Under thrombotic microenvironment (acidic pH and high reactive oxygen species), FA was released to modulate the STING - NLRP3 pathway, suppressing adhesion molecule expression. In a mouse DVT model, Pm@Fng rapidly targeted the endothelium, noticeably reducing thrombosis by 30% (p < 0.001) and preserving endothelial integrity. By exploiting competitive adhesion principles, this study presents a novel therapeutic strategy for DVT and other endothelial injury-related diseases.
- Open Access
- 8 January 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-8
One-stop endovenous laser ablation leads to superior outcomes for varicose veins and iliac vein compression
To retrospectivly investigate the short-term clinical outcomes of one-stop and two-staged endovenous laser ablation (EVLA) procedures for treatment of varicose veins (VVs) and iliac vein compression syndrome (IVCS). In this study, 424 patients were treated for VVs and IVCS from June 2017 to June 2020, 91 underwent one-stop stent angioplasty (SA) and EVLA, 132 underwent two-staged SA and EVLA, 104 underwent one-stop balloon angioplasty (BA) and EVLA, and 97 underwent two-staged BA and EVLA. Clinical outcomes and complications were recorded at 3 and 12 months post-intervention. Quality of life (QoL) was assessed with the venous clinical severity score (VCSS) and Villalta scale. Patients in the SA groups were older (p < 0.05) with higher BMI values (p < 0.05). The incidences of iliac vein stenosis (p < 0.001) and recurrent VVs (p < 0.01) were lower in the one-stop SA group. The VCSS was significantly improved (p < 0.05) at 12 months after the one-stop SA procedure. The one-stop SA procedure effectively relieved symptoms, decreased symptom recurrence, and improved the QoL of patients with VVs and severe IVCS. The two-staged BA procedure is recommended for patients with longer life expectancy.
- 8 January 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-8
Open AccessOne-stop endovenous laser ablation leads to superior outcomes for varicose veins and iliac vein compression
To retrospectivly investigate the short-term clinical outcomes of one-stop and two-staged endovenous laser ablation (EVLA) procedures for treatment of varicose veins (VVs) and iliac vein compression syndrome (IVCS). In this study, 424 patients were treated for VVs and IVCS from June 2017 to June 2020, 91 underwent one-stop stent angioplasty (SA) and EVLA, 132 underwent two-staged SA and EVLA, 104 underwent one-stop balloon angioplasty (BA) and EVLA, and 97 underwent two-staged BA and EVLA. Clinical outcomes and complications were recorded at 3 and 12 months post-intervention. Quality of life (QoL) was assessed with the venous clinical severity score (VCSS) and Villalta scale. Patients in the SA groups were older (p < 0.05) with higher BMI values (p < 0.05). The incidences of iliac vein stenosis (p < 0.001) and recurrent VVs (p < 0.01) were lower in the one-stop SA group. The VCSS was significantly improved (p < 0.05) at 12 months after the one-stop SA procedure. The one-stop SA procedure effectively relieved symptoms, decreased symptom recurrence, and improved the QoL of patients with VVs and severe IVCS. The two-staged BA procedure is recommended for patients with longer life expectancy.
- Open Access
- 1 May 2024
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 11, 1351797
Controlling the nutritional status score: a new tool for predicting postoperative mortality in patients with infrarenal abdominal aortic aneurysm treated with endovascular aneurysm repair
Background: AAA is a fatal condition that commonly occurs during vascular surgery. Nutritional status exerts a significant influence on the prognosis of various pathological conditions Scores from the CONUT screening tool have been shown to predict outcomes of certain malignancies and chronic diseases. However, the ramifications of nutritional status on AAA patients undergoing EVAR have not been elucidated in prior studies. In this study, we aimed to elucidate the correlation between CONUT scores and postoperative prognostic outcomes in patients with AAA undergoing EVAR.Methods: This was a retrospective review of 177 AAA patients treated with EVAR from June 2018 to November 2019 in a single center. Patient characteristics, CONUT scores, and postoperative status were collected. These patients were stratified into groups A and B according to CONUT scores. Subsequently, a comparative analysis of the baseline characteristics between the two cohorts was conducted. Cox proportional hazards and logistic regression analyses were employed to identify the autonomous predictors of mid-term mortality and complications, respectively.Results: Compared with group A, patients in group B had higher midterm mortality (p < 0.001). Univariate analysis showed that CONUT scores; respiratory diseases; stent types; preoperative Hb, CRP, PT, and Fb levels were risk factors for death. Multivariate analysis confirmed that CONUT score [HR, 1.276; 95% CI, 1.029–1.584; p = 0.027] was an independent risk factor for mortality. Logistic regression analysis showed that prior arterial disease, smoking, and D-dimer levels were risk factors, although multivariate analysis showed smoking (OR, 3.492; 95% CI, 1.426–8.553; p = 0.006) was an independent risk factor. Kaplan–Meier curves showed that patients in group B had shorter mid-term survival than those in group A (log-rank p < 0.001).Conclusion: Malnutrition was strongly associated with mid-term mortality in patients with infrarenal AAA treated with EVAR.
- 1 May 2024
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 11, 1351797
Open AccessControlling the nutritional status score: a new tool for predicting postoperative mortality in patients with infrarenal abdominal aortic aneurysm treated with endovascular aneurysm repair
Background: AAA is a fatal condition that commonly occurs during vascular surgery. Nutritional status exerts a significant influence on the prognosis of various pathological conditions Scores from the CONUT screening tool have been shown to predict outcomes of certain malignancies and chronic diseases. However, the ramifications of nutritional status on AAA patients undergoing EVAR have not been elucidated in prior studies. In this study, we aimed to elucidate the correlation between CONUT scores and postoperative prognostic outcomes in patients with AAA undergoing EVAR.Methods: This was a retrospective review of 177 AAA patients treated with EVAR from June 2018 to November 2019 in a single center. Patient characteristics, CONUT scores, and postoperative status were collected. These patients were stratified into groups A and B according to CONUT scores. Subsequently, a comparative analysis of the baseline characteristics between the two cohorts was conducted. Cox proportional hazards and logistic regression analyses were employed to identify the autonomous predictors of mid-term mortality and complications, respectively.Results: Compared with group A, patients in group B had higher midterm mortality (p < 0.001). Univariate analysis showed that CONUT scores; respiratory diseases; stent types; preoperative Hb, CRP, PT, and Fb levels were risk factors for death. Multivariate analysis confirmed that CONUT score [HR, 1.276; 95% CI, 1.029–1.584; p = 0.027] was an independent risk factor for mortality. Logistic regression analysis showed that prior arterial disease, smoking, and D-dimer levels were risk factors, although multivariate analysis showed smoking (OR, 3.492; 95% CI, 1.426–8.553; p = 0.006) was an independent risk factor. Kaplan–Meier curves showed that patients in group B had shorter mid-term survival than those in group A (log-rank p < 0.001).Conclusion: Malnutrition was strongly associated with mid-term mortality in patients with infrarenal AAA treated with EVAR.
- Open Access
- 7 February 2024
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 16 (1) , 1-12
Exosomes derived from BMSCs enhance diabetic wound healing through circ-Snhg11 delivery
Background: Exosomes (Exos) generated from bone mesenchymal stem cells (BMSCs) are elucidated to enhance cutaneous wound healing in mice models of diabetes mellitus (DM). While underlying mechanisms remain unknown. Methods: Next-generation sequencing (NGS) was used to examine changes in circRNA expression levels following Exo treatment. Luciferase assays were used to determine the interactions between RNAs. Immunofluorescence staining was used to examine reactive oxygen species (ROS) in endothelial progenitor cells (EPCs) cultured in high glucose (HG) conditions. Therapeutic effects regarding Exos were also examined by immunofluorescence. Results: We found that Exo treatment enhanced cutaneous wound healing significantly. NGS indicated that circ-Snhg11 was involved in Exo-mediated tissue repairing. Downregulation of circ-Snhg11 decreased Exo-mediated therapy responses during wound healing in diabetic mouse. Our luciferase reporter data confirmed that SLC7A11 and miR-144-3p were circ-Snhg11 downstream targets. miR-144-3p overexpression or SLC7A11 knockdown altered the protective effects of circ-Snhg11 upon EPCs exposed to HG conditions. Upregulation of circ-Snhg11 incremented therapy effects of Exo treatment during wound healing in DM mice through enhanced angiogenesis along with a reduction in GPX4-mediated ferroptosis. Conclusions: circ-Snhg11 in BMSC-Exos enhanced SLC7A11/GPX4-mediated anti-ferroptosis signals via miR-144-3p sponging resulting in enhanced diabetic wound healing and improved angiopoiesis.
- 7 February 2024
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 16 (1) , 1-12
Open AccessExosomes derived from BMSCs enhance diabetic wound healing through circ-Snhg11 delivery
Background: Exosomes (Exos) generated from bone mesenchymal stem cells (BMSCs) are elucidated to enhance cutaneous wound healing in mice models of diabetes mellitus (DM). While underlying mechanisms remain unknown. Methods: Next-generation sequencing (NGS) was used to examine changes in circRNA expression levels following Exo treatment. Luciferase assays were used to determine the interactions between RNAs. Immunofluorescence staining was used to examine reactive oxygen species (ROS) in endothelial progenitor cells (EPCs) cultured in high glucose (HG) conditions. Therapeutic effects regarding Exos were also examined by immunofluorescence. Results: We found that Exo treatment enhanced cutaneous wound healing significantly. NGS indicated that circ-Snhg11 was involved in Exo-mediated tissue repairing. Downregulation of circ-Snhg11 decreased Exo-mediated therapy responses during wound healing in diabetic mouse. Our luciferase reporter data confirmed that SLC7A11 and miR-144-3p were circ-Snhg11 downstream targets. miR-144-3p overexpression or SLC7A11 knockdown altered the protective effects of circ-Snhg11 upon EPCs exposed to HG conditions. Upregulation of circ-Snhg11 incremented therapy effects of Exo treatment during wound healing in DM mice through enhanced angiogenesis along with a reduction in GPX4-mediated ferroptosis. Conclusions: circ-Snhg11 in BMSC-Exos enhanced SLC7A11/GPX4-mediated anti-ferroptosis signals via miR-144-3p sponging resulting in enhanced diabetic wound healing and improved angiopoiesis.
- Open Access
- 6 December 2023
- Published by Springer Nature in Thrombosis Journal
- Vol. 21 (1) , 1-8
Comparison between canine and porcine models of chronic deep venous thrombosis
Objective: To first induce chronic deep venous thrombosis in the left iliac veins of canines and porcines and then compare these two models to validate endovascular treatment devices. Methods: Thrombin and fibrinogen were used to produce a solid thrombus in the left iliac veins of a stenosis model. The researchers used venous angiography and histological staining to investigate the progression of thrombosis. Results: A left iliac vein thrombus was successfully formed in all experimental animals, including six Labrador dogs and three Bama miniature pigs, and there was minimal surgical bleeding. All dogs survived until 90 days, and three pigs died on Days 29, 33, and 58. Conclusion: The researchers first established the models and then observed the progression of chronic deep venous thrombosis of the iliac vein in large animals for up to 90 days. Dogs are better suited for chronic deep venous thrombosis models due to their uncomplicated anatomy, excellent obedience, and proneness to physical activity compared with pigs.
- 6 December 2023
- Published by Springer Nature in Thrombosis Journal
- Vol. 21 (1) , 1-8
Open AccessComparison between canine and porcine models of chronic deep venous thrombosis
Objective: To first induce chronic deep venous thrombosis in the left iliac veins of canines and porcines and then compare these two models to validate endovascular treatment devices. Methods: Thrombin and fibrinogen were used to produce a solid thrombus in the left iliac veins of a stenosis model. The researchers used venous angiography and histological staining to investigate the progression of thrombosis. Results: A left iliac vein thrombus was successfully formed in all experimental animals, including six Labrador dogs and three Bama miniature pigs, and there was minimal surgical bleeding. All dogs survived until 90 days, and three pigs died on Days 29, 33, and 58. Conclusion: The researchers first established the models and then observed the progression of chronic deep venous thrombosis of the iliac vein in large animals for up to 90 days. Dogs are better suited for chronic deep venous thrombosis models due to their uncomplicated anatomy, excellent obedience, and proneness to physical activity compared with pigs.
- 6 August 2023
- Published by Elsevier in Cellular Signalling
- Vol. 111, 110843
miR-138 from ADSC Exo accelerates wound healing by targeting SIRT1/PTEN pathway to promote angiogenesis and fibrosis
- 6 August 2023
- Published by Elsevier in Cellular Signalling
- Vol. 111, 110843
miR-138 from ADSC Exo accelerates wound healing by targeting SIRT1/PTEN pathway to promote angiogenesis and fibrosis
- Open Access
Comparison between Canine and Porcine Models of Chronic Deep Venous Thrombosis
Venous thromboembolism(VTE) refers to deep venous thrombosis(DVT) and pulmonary embolism(PE), which is a worldwide problem and has very high morbidity and mortality. The research of venous thrombosis involves pathogenesis, pathophysiology, and therapeutic attempt. Alternative experimental animal models have changed dramatically over the past 20 years, from small murine models to large ones. Larger animal models offer more options and are more consistent with human physiology. This article aims to induce chronic deep venous thrombosis in the left iliac vein in canine and porcine models and compare these two models. We think that feasible large animal models can better translate the results of therapeutic research into clinical application.
Open AccessComparison between Canine and Porcine Models of Chronic Deep Venous Thrombosis
Venous thromboembolism(VTE) refers to deep venous thrombosis(DVT) and pulmonary embolism(PE), which is a worldwide problem and has very high morbidity and mortality. The research of venous thrombosis involves pathogenesis, pathophysiology, and therapeutic attempt. Alternative experimental animal models have changed dramatically over the past 20 years, from small murine models to large ones. Larger animal models offer more options and are more consistent with human physiology. This article aims to induce chronic deep venous thrombosis in the left iliac vein in canine and porcine models and compare these two models. We think that feasible large animal models can better translate the results of therapeutic research into clinical application.
- Open Access
- 25 May 2022
- Published by Springer Nature in Research Square
BMSC derived exosomes accelerate diabetic wound healing via circ-Snhg11 delivery
Background: Exosome (Exo) secreted by bone mesenchymal stem cells (BMSCs) enhances cutaneous wound healing in mouse with diabetes mellitus (DM). However, the mechanism remains unclear. Methods: Next-generation sequencing (NGS) was applied to study abnormal circular RNA (circRNA) expressions in ulcer tissues with or without Exo treatment. Bioinformatics and luciferase outputs were employed to verify interactional correlations amongst RNAs. EPCs cells were utilized to study the ROS under high glucose conditions by immunofluorescence. A DM ulceration mouse model was established and the therapeutic Exo effect was investigated through immunofluorescence. Results: Data showcased that Exo treatment significantly promoted cutaneous wound healing in mice with DM. NGS discovered that circ-Snhg11 functioned in Exo-mediated tissues repair. circ-Snhg11 downregulation reduced therapeutic effects regarding Exo upon wound healing in diabetic mice. Bioinformatics and luciferase reporting outcomes verified that both miR-144-3p and SLC7A11 were circ-Snhg11 downstream targets. SLC7A11 downregulation or miR-144-3p overexpression reversed protective effect regarding circ-Snhg11 on EPCs after exposure to a high glucose microenvironment. circ-Snhg11 upregulation increased the therapeutic Exo effect on wound healing in diabetic mice by stimulating angiogenesis and reducing GPX4-mediated ferroptosis. Furthermore, Exo circ-Snhg11 delivery promoted the miR-144-3p/SLC7A11/GPX4 signal. Conclusions: In conclusion, circ-Snhg11 from BMSC Exo promoted the SLC7A11/GPX4-mediated anti-ferroptosis signal by sponging miR-144-3p. This promoted angiopoiesis and accelerated diabetic wound healing.
- 25 May 2022
- Published by Springer Nature in Research Square
Open AccessBMSC derived exosomes accelerate diabetic wound healing via circ-Snhg11 delivery
Background: Exosome (Exo) secreted by bone mesenchymal stem cells (BMSCs) enhances cutaneous wound healing in mouse with diabetes mellitus (DM). However, the mechanism remains unclear. Methods: Next-generation sequencing (NGS) was applied to study abnormal circular RNA (circRNA) expressions in ulcer tissues with or without Exo treatment. Bioinformatics and luciferase outputs were employed to verify interactional correlations amongst RNAs. EPCs cells were utilized to study the ROS under high glucose conditions by immunofluorescence. A DM ulceration mouse model was established and the therapeutic Exo effect was investigated through immunofluorescence. Results: Data showcased that Exo treatment significantly promoted cutaneous wound healing in mice with DM. NGS discovered that circ-Snhg11 functioned in Exo-mediated tissues repair. circ-Snhg11 downregulation reduced therapeutic effects regarding Exo upon wound healing in diabetic mice. Bioinformatics and luciferase reporting outcomes verified that both miR-144-3p and SLC7A11 were circ-Snhg11 downstream targets. SLC7A11 downregulation or miR-144-3p overexpression reversed protective effect regarding circ-Snhg11 on EPCs after exposure to a high glucose microenvironment. circ-Snhg11 upregulation increased the therapeutic Exo effect on wound healing in diabetic mice by stimulating angiogenesis and reducing GPX4-mediated ferroptosis. Furthermore, Exo circ-Snhg11 delivery promoted the miR-144-3p/SLC7A11/GPX4 signal. Conclusions: In conclusion, circ-Snhg11 from BMSC Exo promoted the SLC7A11/GPX4-mediated anti-ferroptosis signal by sponging miR-144-3p. This promoted angiopoiesis and accelerated diabetic wound healing.
- Open Access
- 1 November 2021
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 35 (11) , 108020
Circ-Klhl8 overexpression increased the therapeutic effect of EPCs in diabetic wound healing via the miR-212-3p/SIRT5 axis
- 1 November 2021
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 35 (11) , 108020
Open AccessCirc-Klhl8 overexpression increased the therapeutic effect of EPCs in diabetic wound healing via the miR-212-3p/SIRT5 axis